As life sciences slowly emerges from the recession, new investment models are being introduced into the industry. Companies looking for financing or acquisition need to be mindful of new valuation strategies and ensure their business models and product development strategies reflect these new tactics. Moreover, investors are feeling the pressures of the challenging regulatory environment, health care reform and changes inside big pharma which are impacting their investment strategies. During this session, speakers will touch on the following aspects of venture funding, private equity and M&A transactions:
-
Strategic acquisitions in today’s economy; what acquirers are looking for
-
Successful exit strategies in a changing market
-
Evolving deal structures
-
How VC’s are positioning their portfolio companies for exits
-
Current financial and regulatory pressures driving investor behavior
-
Life Sciences IPOs: Are they an exit strategy option?
-
The availability of capital in the current market
-
Developing business models that address today’s market challenges and position a company for success
Moderated by:
James C. Chapman , Partner, Foley & Lardner LLP
Speakers:
Camille D.Samuels, Managing Director, Versant Ventures
David M. Sabow, Vice President, Investment Banking, Canaccord Genuity Inc.
Rich Ramko, Partner, Ernst & Young